Biogen Halves Price Of Alzheimer’s Drug To $28,200

Biogen Inc (BIIB.O) on Monday cut the price of its Alzheimer’s drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.

The U.S. Food and Drug Administration (FDA) approved the drug, Aduhelm, in June to treat the brain-wasting disease despite the view of its outside advisory panel that Biogen had not proven the treatment’s clinical benefit.

The U.S. Medicare program, which pays for health services for people over 65 years, has scheduled a January meeting for a national policy for the drug, making reimbursement more difficult in the interim.

Biogen’s $56,000 per year treatment price for an average weight person was seen as a significant cost burden on Medicare, which covers more than 60 million people.

The company said it hoped the new annual price of $28,200 will expand access to the drug among patients.

Biogen has been betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to buffer a hit from its main revenue drivers facing rising competition.

Aduhelm brought in sales of $300,000 in the latest quarter, missing analysts’ estimates.

“We are big fans of Biogen’s decision to cut the price of Aduhelm, and, in our view, this makes some level of reasonable Medicare reimbursement more likely,” Stifel analyst Paul Matteis said.

Biogen said with insurance coverage and access to diagnostics and specialized centers roughly 50,000 patients may begin treatment with Aduhelm in 2022.

The FDA had initially approved the drug for all Alzheimer’s patients, but later recommended its use only in patients with mild cognitive impairment or mild dementia.

Biogen also announced cost-reduction measures for 2022 that could result in annual savings of about $500 million.

 

Source Link

Recommended Articles

Annual Employee Benefits Compliance Responsibilities On January 1st

The start of each year marks an important date for employers as they face annual compliance responsibilities related to their health plans, the Affordable Care Act (ACA), and COBRA. Staying on top of these regulations is crucial for compliance and to avoid significant non-compliance penalties.

Read More

AI in Healthcare: Calls for Stricter Standards Amid OpenAI Leadership Shuffle

Recent disruptions in OpenAI’s top brass have sparked intense dialogue within the healthcare sector, emphasizing the urgent need for robust standards governing the implementation of generative AI technologies. With Microsoft recruiting former OpenAI executives Sam Altman and Greg Brockman, concerns are growing that few corporations may soon dictate the trajectory of healthcare AI, potentially molding ...

Read More

2024 FSA, HSA, and HDHP Plan Limits

A health Flexible Spending Account (FSA) is an employer-sponsored benefit that allows eligible employees to save pre-tax dollars to pay for qualified medical expenses. Employees can elect a specific dollar amount, up to a certain limit, to set aside annually.

Read More

Proposals On PBMs And Medical Devices Advanced By House Subcommittee

The House Committee on Energy and Commerce health subcommittee pushed forward 21 proposals on Tuesday, some of which will restrict the power of pharmacy benefit managers (PBMs). Democrats supported many of the proposals put forward by Republicans, including legislation reining in PBMs that had support from 60 organizations representing patients, providers, pharmacists, small businesses and ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square